Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fibrinogen Deficiency Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

NCT02267226
View directory record Official record
Conditions
Congenital Fibrinogen Deficiency
Interventions
Octafibrin
Drug
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Jul 22, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Human Fibrinogen - Pharmacokinetics

NCT00496262
View directory record Official record
Conditions
Fibrinogen Deficiency
Interventions
Human Fibrinogen Concentrate
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Aurora, Colorado • St. Petersburg, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jul 22, 2026, 6:53 AM EDT
Terminated No phase listed Observational

Screening Study to Identify Patients With Complement Factor I Deficiencies

NCT05072912
View directory record Official record
Conditions
Previous Diagnosis With a Complement-mediated Disease and/or With Clinical Manifestations Reasonably Associated With Complement Factor I Deficiency
Interventions
Not listed
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
6 Months and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Jul 22, 2026, 6:53 AM EDT
Completed No phase listed Observational

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency

NCT02427217
View directory record Official record
Conditions
Congenital Fibrinogen Deficiency
Interventions
FCH
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Jul 22, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

NCT01575756
View directory record Official record
Conditions
Congenital Fibrinogen Deficiency, Afibrinogenemia
Interventions
Octafibrin, Haemocomplettan® P or RiaSTAPTM
Biological
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Jul 22, 2026, 6:53 AM EDT
Terminated Not applicable Interventional Results available

Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions

NCT02540434
View directory record Official record
Conditions
Coagulopathy
Interventions
ROTEM, Cryoprecipitate, RiaSTAP
Device · Other · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jul 22, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence

NCT05634005
View directory record Official record
Conditions
Anemia, Thrombocytopenia, Coagulopathy, Mild, Hypofibrinogenemia
Interventions
Clinical Decision Support
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1,543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jul 22, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding

NCT05711524
View directory record Official record
Conditions
Hypofibrinogenemia, Bleeding
Interventions
Traditional Cryoprecipitate, Pathogen-Reduced Cryoprecipitate
Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 22, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Human Fibrinogen Concentrate in Pediatric Cardiac Surgery

NCT02822599
View directory record Official record
Conditions
Hypofibrinogenemia, Afibrinogenemia, Bleeding Disorders
Interventions
RiaStAP, Saline
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
1 Day to 1 Year
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Jul 22, 2026, 6:53 AM EDT
Not yet recruiting No phase listed Observational

Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage

NCT07218185
View directory record Official record
Conditions
Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
Interventions
Pathogen Reduced Cryoprecipitated Fibrinogen Complex
Biological
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Aurora, Colorado • Miami, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 6:53 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

NCT01811576
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
TV-1106, Recombinant human growth hormone
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
23 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Jul 22, 2026, 6:53 AM EDT
Completed Early Phase 1 Interventional

Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates

NCT00517062
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Growth hormone (Genotropin), Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Jul 22, 2026, 6:53 AM EDT
Recruiting No phase listed Observational

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

NCT00903110
View directory record Official record
Conditions
IGF1 Deficiency
Interventions
Increlex®
Drug
Lead sponsor
Esteve Pharmaceuticals, S.A.
Industry
Eligibility
2 Years to 18 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
7
States / cities
Orange, California • Miami, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 22, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

NCT00572156
View directory record Official record
Conditions
Insulin-like Growth Factor-1 Deficiency
Interventions
NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Drug
Lead sponsor
Ipsen
Industry
Eligibility
5 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Jul 22, 2026, 6:53 AM EDT
Terminated No phase listed Observational

A Natural History Study to Assess the Clinical Outcomes of Patients With Complement Factor I Deficiency-Mediated Disease

NCT05095623
View directory record Official record
Conditions
Recurrent Bacterial Infection, Autoimmune Disorder
Interventions
Natural History Observation
Other
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
6 Months and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Jul 22, 2026, 6:53 AM EDT